Top Ten most popular articles on Pharmafile.com this week
pharmafile | October 19, 2018 | News story | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing | AI, AstraZeneca, Bayer, Novartis, Samsung, Trump, biosimilars, brexit
Business, biosimilars and Brexit are the themes of this week’s top 10. While Roche signed a $1 billion deal with SQZ Biotech, MSD’s and Samsung Bioepis’ deal fell through. Meanwhile Pfizer announced a cull of 2% of its staff amid a widespread restructuring.
However this week’s pharma deals were overshadowed by the news surrounding biosmilars as Amgen launched the world’s first biosimilar of the world’s bestselling drug Humira. Meanwhile Trump launched legislation against monopoly biosimilar firms. Nevertheless it was Brexit that took the top spot after AstraZeneca were revealed to have halted investment into the United Kingdom.
Check out this week’s top ten stories on Pharmafile.com now!
10. MSD and Samsung Bioepis terminate development of Lantus biosimilar for diabetes
MSD has reportedly terminated a previous agreement with Samsung Bioepis which would have seen them collaborate on a biosimilar version of Sanofi’s Lantus (insulin glargine) for diabetes.
9. Trump signs trust-busting biosimilar bill into law
President Donald J Trump has signed off a law which requires drugmakers and pharma firms to reveal the details of biosimilar deals to the US’ independent trust-busting agency the Federal Trade Commission (FTC).
8. Pfizer announce cull of 2% of staff
US pharma giant Pfizer is offering early retirement to American workers ahead of layoffs scheduled for next year.
7. Samsung and Bioepis launch third Humira biosimilar in Europe
Hot on the heels of Amgen, Samsung Bioepis and Biogen have announced the launch of their own biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) in Europe.
6. Novartis and Bayer seek to oppose High Court ruling over NHS decision to use cheaper drug
Swiss multinational Novartis have joined German pharma firm Bayer in appealing a High Court ruling over 12 NHS clinical commissioning groups (CCGs) decision to use a cheaper alternative to the two company’s treatments for wet AMD.
5. Amgen launches first biosimilar of best-selling Humira in Europe
Amgen has announced the launch of a proprietary biosimilar version of Abbvie’s best-selling drug Humira (adalimumab) across all European markets, beginning 16 October.
4. Roche signs $1 billion deal with cell therapy firm SQZ biotech
The Massachusetts-based cell therapy company SQZ Biotech, has announced the expansion of its collaboration with Swiss pharma giant Roche, in a deal that could be worth up to $1 billion.
3. AI, big data: Making a case for faster drug discovery
They’re two of the biggest buzzwords getting professionals excited across pharma – Anjali Shukla explores the ways in which AI and big data are set to galvanise the industry.
2. Prescription painkillers reclassified amid addiction concerns
Two commonly prescribed painkillers are set to be put under tighter controls in the United Kingdom after a number of deaths were linked to their use.
1. AstraZeneca halting UK investment due to Brexit uncertainty
The Anglo-Swedish pharma firm AstraZeneca has suspended investment into the United Kingdom, due to the uncertainty surrounding Brexit.
Related Content
AstraZeneca’s Tagrisso approved in Japan for lung cancer treatment
AstraZeneca has announced that Tagrisso (osimertinib) in combination with pemetrexed and platinum-based chemotherapy has been …
AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) …
AstraZeneca shares results from phase 3 TROPION-Lung01 trial
AstraZeneca has announced results from the phase 3 TROPION-Lung01 trial of AstraZeneca and Daiichi Sankyo’s …
